Linoleoyl ethanolamide reduces lipopolysaccharide-induced inflammation in macrophages and ameliorates 2,4-dinitrofluorobenzene-induced contact dermatitis in mice.
Tsukasa Ishida, Shin Nishiumi, Toshihito Tanahashi, Akifumi Yamasaki, Asahi Yamazaki, Takahiro Akashi, Ikuya Miki, Yasuyuki Kondo, Jun Inoue, Shoji Kawauchi, Takeshi Azuma, Masaru Yoshida, Shigeto Mizuno
文献索引:Eur. J. Pharmacol. 699(1-3) , 6-13, (2013)
全文:HTML全文
摘要
In our previous study, it was found that linoleoyl ethanolamide (LE) is present in sake lees, which are produced as a byproduct during the making of Japanese sake. LE is a fatty acid ethanolamide, which have been demonstrated to exert a variety of biological functions, and in this study, the anti-inflammatory effects of LE were examined using in vitro cell culture and in vivo animal experiments. In mouse RAW264.7 macrophages, LE suppressed the lipopolysaccharide (LPS)-induced expression of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6. In addition, LE inhibited LPS-induced increases in the levels of cyclooxygenase enzyme-2 and prostaglandin E(2), which are indicators of inflammation. The inhibitory effect of LE on the release of TNF-α was stronger than that of dipotassium glycyrrhizinate, which is widely used in external human skin care treatments. LE also suppressed the LPS-induced activation of Toll-like receptor 4 signaling and nuclear translocation of nuclear factor-κB (NF-κB) p65. In a contact dermatitis animal model, applying LE to affected ear skin ameliorated 2,4-dinitrofluorobenzene-induced contact dermatitis and pro-inflammatory cytokine expression at inflamed sites. These results indicate that LE exerts anti-inflammatory effects by inhibiting NF-κB signaling, and LE is proposed to be a useful therapeutic agent against contact dermatitis.Copyright © 2012 Elsevier B.V. All rights reserved.
相关化合物
相关文献:
2014-12-15
[J. Exp. Med. 211(13) , 2549-66, (2014)]
2014-11-01
[J. Invest. Dermatol. 134(11) , 2709-18, (2014)]
2015-03-01
[Clin. Exp. Immunol. 179(3) , 485-99, (2015)]
2014-11-01
[Drug Dev. Ind. Pharm. 40(11) , 1538-46, (2014)]
2014-01-01
[Int. J. Nanomedicine 9 , 5143-56, (2014)]